Hattingen, E., Jurcoane, A., Daneshvar, K., Pilatus, U., Mittelbronn, M., Steinbach, J. P., & Bähr, O. (2013). Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Oxford University Press.
Chicago Style CitationHattingen, Elke, Alina Jurcoane, Keivan Daneshvar, Ulrich Pilatus, Michel Mittelbronn, Joachim P. Steinbach, i Oliver Bähr. Quantitative T2 Mapping of Recurrent Glioblastoma Under Bevacizumab Improves Monitoring for Non-enhancing Tumor Progression and Predicts Overall Survival. Oxford University Press, 2013.
Cita MLAHattingen, Elke, et al. Quantitative T2 Mapping of Recurrent Glioblastoma Under Bevacizumab Improves Monitoring for Non-enhancing Tumor Progression and Predicts Overall Survival. Oxford University Press, 2013.